Mineralys Therapeutics (MLYS) Change in Accured Expenses (2022 - 2026)

Mineralys Therapeutics has reported Change in Accured Expenses for 5 years, with the latest figure at -$402000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 74.0% year-over-year to -$402000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 127.16% YoY) and the FY2025 annual result came in at $427000.0, down 89.74% from the prior year.
• Change in Accured Expenses improved to -$402000.0 in Q1 2026 per MLYS's latest filing, from -$8.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $9.5 million in Q2 2024 and troughed at -$16.7 million in Q4 2024.
• A 5-year average of $565588.2 and a median of $864000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 2627.14% in 2023, down 465.15% in 2023.
• Over 5 years, Change in Accured Expenses stood at $846000.0 in 2022, then plunged by 461.82% to -$3.1 million in 2023, then sank by 444.72% to -$16.7 million in 2024, then soared by 51.24% to -$8.1 million in 2025, then soared by 95.06% to -$402000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$402000.0, -$8.1 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.